Angitia Biopharmaceuticals Presents Data From Phase 1/2 Study Of AGA111 At 2025 AAOS Annual Meeting
AGA111 treatment resulted in high spinal fusion success rate and improved functional outcomesWOODLAND HILLS, Calif., March 18, 2025 (GLOBE ...